Study: Semaglutide’s Promising Role in Alcohol Use Disorder
The first evidence of semaglutide’s specific efficacy in alleviating symptoms of Alcohol Use Disorder (AUD) has been published in The Journal of Clinical Psychiatry.
Read More
Amgen and Viking Therapeutics Set to Join the Obesity Drug Arena
Amgen and Viking are developing obesity medications that show promise in early trials, with Amgen’s drug demonstrating a 14.5% weight loss over 12 weeks and Viking’s achieving an 8% reduction over 28 days.
Pfizer Halts Development of Obesity Drug Danuglipron Amid High Side Effect Rates
Pfizer has decided to halt the advancement of danuglipron following a challenging Phase 2b clinical trial, primarily the high incidence of adverse side effects.
EMA Scrutinizes Ozempic & Wegovy for Link to Suicidal Thoughts
The European Medicines Agency (EMA) is scrutinizing of Ozempic and Wegovy for possible links to suicidal thoughts. The investigation was spurred by reports from the Icelandic Medicines Agency and EudraVigilance.
Study: GLP-1 Receptor Agonists Impact on Bowel Preparation for Colonoscopy
A recent study published in The American Journal of Gastroenterology has revealed a significant association between GLP-1RAs and lower quality of bowel prep for colonoscopies.
Biohaven Trying to Launch GLP-1 Drug That Saves Muscles
While GLP-1 agonists are known for their effective weight loss results, they come with significant drawbacks, including loss of lean muscle mass. Taldefgrobep alfa, a myostatin inhibitor licensed from Bristol Myers Squibb, stands apart by targeting not just fat loss but also muscle preservation.
Why is Eli Lilly Giving Mounjaro a Second Name?
Eli Lilly is adopting a unique marketing approach for tirzepatide, known as Mounjaro for type 2 diabetes and Zepbound for weight loss.